Global CD25 (IL2R alpha) Antibody Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global CD25 (IL2R alpha) Antibody market size was valued at US$ 507 million in 2024 and is forecast to a readjusted size of USD 1120 million by 2031 with a CAGR of 12.1% during review period.

CD25 (IL2R alpha) Antibody is an antibody directed against the CD25 protein (interleukin-2 receptor alpha chain) in the human immune system.

CD25 is the α subunit of the IL-2 receptor and is widely expressed on the surface of regulatory T cells (Tregs) and other activated immune cells. The binding of this antibody can interfere with IL-2 signaling and affect cell proliferation, differentiation and immune response, especially the negative regulation of immune response. Therefore, CD25 antibody is used as a potential tool for immunomodulatory therapy aimed at modulating the activity of the immune system for the treatment of autoimmune diseases, organ transplant rejection and other diseases, as well as possible applications in the treatment of certain tumors. This makes CD25 antibodies one of the areas of great interest in immunotherapy research.

This report is a detailed and comprehensive analysis for global CD25 (IL2R alpha) Antibody market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global CD25 (IL2R alpha) Antibody market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global CD25 (IL2R alpha) Antibody market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global CD25 (IL2R alpha) Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global CD25 (IL2R alpha) Antibody market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for CD25 (IL2R alpha) Antibody

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global CD25 (IL2R alpha) Antibody market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sino Biological, Inc., LifeSpan BioSciences, Inc, Bio-Techne, Abeomics Inc., Abcam, Boster Biological Technology, MyBiosource, Inc., BioLegend, Abbexa, Merck, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

CD25 (IL2R alpha) Antibody market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Monoclonal Antibody

Polyclonal Antibody

Market segment by Application

Flow Cytometry

ELISA

Western Blot

Immunoprecipitation

Immunofluorescence

Others

Major players covered

Sino Biological, Inc.

LifeSpan BioSciences, Inc

Bio-Techne

Abeomics Inc.

Abcam

Boster Biological Technology

MyBiosource, Inc.

BioLegend

Abbexa

Merck

Arigo Biolaboratories Corp.

Leinco Technologies

Diagnostic BioSystems

Creative Diagnostics

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe CD25 (IL2R alpha) Antibody product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of CD25 (IL2R alpha) Antibody, with price, sales quantity, revenue, and global market share of CD25 (IL2R alpha) Antibody from 2020 to 2025.

Chapter 3, the CD25 (IL2R alpha) Antibody competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the CD25 (IL2R alpha) Antibody breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and CD25 (IL2R alpha) Antibody market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of CD25 (IL2R alpha) Antibody.

Chapter 14 and 15, to describe CD25 (IL2R alpha) Antibody sales channel, distributors, customers, research findings and conclusion.